A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy (DMD)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Ifetroban (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Cumberland Pharmaceuticals
- 01 Feb 2018 Planned number of patients changed from 32 to 48.
- 01 Feb 2018 Planned End Date changed from 1 Jul 2019 to 1 Nov 2021.
- 01 Feb 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Nov 2021.